Table 3.
Outcome |
Mid‐life vascular risk Model 1 |
Mid‐life vascular risk Model 2 |
Late‐life vascular risk Model 3 |
|||
---|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
Cerebrovascular pathology | ||||||
Cortical infarcts | 3.99 (1.65, 9.65) | 0.002* | 3.83 (1.55, 9.45) | 0.004* | 1.04 (1.00, 1.08) | 0.049* |
Subcortical infarcts | 1.95 (1.07, 3.54) | 0.029* | 1.85 (1.01, 3.40) | 0.047* | 1.02 (0.99, 1.06) | 0.129 |
Atherosclerosis | 1.89 (1.17, 3.06) | 0.009* | 1.90 (1.16, 3.10) | 0.011* | 1.02 (1.00, 1.05) | 0.070 |
Arteriosclerosis | 1.86 (1.15, 3.02) | 0.012* | 1.78 (1.09, 2.90) | 0.022* | 1.03 (1.00, 1.05) | 0.024* |
Proteinopathy | ||||||
Braak NFT stage | 1.15 (0.73, 1.82) | 0.554 | 1.18 (0.74, 1.89) | 0.484 | 1.03 (1.01, 1.05) | 0.012* |
Cerebral amyloid angiopathy | 1.15 (0.71, 1.86) | 0.575 | 1.19 (0.72, 1.95) | 0.494 | 1.02 (1.00, 1.05) | 0.061 |
CERAD neuritic plaque score | 0.86 (0.54, 1.37) | 0.525 | 0.86 (0.54, 1.39) | 0.547 | 1.02 (1.00, 1.05) | 0.052 |
OR, Odds ratio; CI, confidence interval; P, P‐value; CERAD, Consortium to Establish a Registry for Alzheimer's Disease.
Model 1: Adjusted for gender, presence of ApoE ɛ4, and elapsed time between mid‐life vascular risk and death (with quadratic term for atherosclerosis and arteriosclerosis).
Model 2: Model 1 additionally adjusted for late‐life vascular risk.
Model 3: Adjusted for gender, presence of ApoE ɛ4, and elapsed time between late‐life vascular risk and death.
P < 0.05.